NEW YORK/AMSTERDAM - AtaiBeckley N.V. (NASDAQ:ATAI) announced Monday positive topline results from the open-label extension study of its Phase 2b clinical trial for BPL-003, a mebufotenin benzoate ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Starting a new job search? Take the first step with these resume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback